Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery
October 07, 2019 08:00 ET
|
Oculis SA
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone also in a Phase 2b trial for diabetic macular edema (DME) LAUSANNE, Switzerland, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Oculis...
Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Board
September 17, 2019 08:00 ET
|
Oculis SA
-- Eric D. Donnenfeld, M.D., internationally recognized expert and pioneer in refractive, cornea and cataract surgery -- Ramin Tadayoni, M.D., Ph.D., renowned professor and ophthalmologist in the...